A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

Inclusion Criteria

• •Patients with previously treated or newly diagnosed follicular center cell grade I or grade II lymphoma, small lymphocytic lymphoma, MALT lymphoma, monocytoid B-cell lymphoma, Waldenstrom's macroglobulinemia, or marginal zone lymphoma with bidimensionally measurable disease;
• •Part of the resected specimen must undergo routine pathologic examination to confirm the diagnosis of lymphoma. The remaining tissue must be used for the preparation of autologous HSPPC-96;
• •Autologous HSPPC-96 vaccine must be successfully prepared and provided by the sponsor;
• •A minimum of 2 grams of non-necrotic, resectable malignant lymphoma for HSPPC-96 preparation;
• •Bidimensionally measurable disease in at least one location other than the resected lymphoid tissue;
• •Life expectancy of at least 16 weeks;
• •Zubrod performance status of less then or equal to 2;
• •Adequate bone marrow function;
• •Adequate hepatic function;
• •Adequate renal function;
• •Signed written informed consent;
• •Patients of child-bearing potential must practice contraception, which is adequate in the opinion of the Principal Investigator;
• •Patients of child-bearing potential must have a negative serum pregnancy test prior to entry into the study and must not be lactating;
• •Patients must be willing to be followed at the M. D. Anderson Cancer Center during the course of treatment and follow-up;
• •Electrocardiogram if none performed in the prior six months;
• •Patients must have no chemotherapy, immunotherapy, radiotherapy, or experimental anti-cancer therapy within six weeks prior to starting autologous HSPPC-96 administration;
• •Patients must have fully recovered from prior anti-cancer therapy;
• •Tumor measurements and staging no more than 4 weeks prior to receiving the first dose of autologous HSPPC-96.